Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Rheumatoid Arthritis (Feb 2019)

Posted by Matt Breese on Feb 15, 2019

According to our recent payer coverage analysis for rheumatoid arthritis (RA) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Market Access, Branding & Marketing, Specialty, Payer

MMIT Reality Check on Type 2 Diabetes (Feb 2019)

Posted by Matt Breese on Feb 8, 2019

According to our recent payer coverage analysis for type 2 diabetes treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Market Access, Branding & Marketing, Specialty, Payer

MMIT Reality Check on Neutropenia (Feb 2019)

Posted by Matt Breese on Feb 1, 2019

According to our recent payer coverage analysis for neutropenia treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Market Access, Branding & Marketing, Specialty, Payer

MMIT Reality Check on Hemophilia (Jan 2019)

Posted by Matt Breese on Jan 25, 2019

According to our recent payer coverage analysis for hemophilia treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Market Access, Branding & Marketing, Specialty, Payer

MMIT Reality Check on PCSK9 (Jan 2019)

Posted by Matt Breese on Jan 18, 2019

According to our recent payer coverage analysis for PCSK9 inhibitors, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Market Access, Branding & Marketing, Specialty, Payer

MMIT Reality Check on Multiple Sclerosis (Jan 2019)

Posted by Matt Breese on Jan 11, 2019

According to our recent payer coverage analysis for multiple sclerosis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Market Access, Branding & Marketing, Specialty, Payer

MMIT Reality Check on Immune Globulin PID (Jan 2019)

Posted by Matt Breese on Jan 4, 2019

According to our recent payer coverage analysis for immune globulins for primary immunodeficiency (PID), combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Market Access, Branding & Marketing, Specialty

MMIT Reality Check on Epilepsy (Dec 2018)

Posted by Matt Breese on Dec 28, 2018

According to our recent payer coverage analysis for epilepsy treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Market Access, Branding & Marketing, Specialty, Payer

MMIT Reality Check on Alpha-1 Antitrypsin Deficiency (Dec 2018)

Posted by Matt Breese on Dec 21, 2018

According to our recent payer coverage analysis for alpha-1 antitrypsin deficiency treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Market Access, Branding & Marketing, Specialty, Payer

MMIT Reality Check on Prostate Cancer (Dec 2018)

Posted by Matt Breese on Dec 14, 2018

According to our recent payer coverage analysis for prostate cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Market Access, Branding & Marketing, Specialty, Payer